These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17681094)

  • 1. Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer.
    Ho C; Davies A; Mack P; Gandara D
    Clin Lung Cancer; 2007 Jul; 8(7):420-4. PubMed ID: 17681094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR inhibition in NSCLC: the emerging role of cetuximab.
    Herbst RS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
    Saba NF; Khuri FR; Shin DM
    Oncology (Williston Park); 2006 Feb; 20(2):153-61; discussion 162, 166, 169 passim. PubMed ID: 16562649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Bar J; Onn A
    Clin Lung Cancer; 2012 Jul; 13(4):267-79. PubMed ID: 22154113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
    Langer CJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.
    Giaccone G
    J Clin Oncol; 2005 May; 23(14):3235-42. PubMed ID: 15886311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
    Harari PM; Huang S
    Semin Radiat Oncol; 2006 Jan; 16(1):38-44. PubMed ID: 16378905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC.
    Rogers SJ; Harrington KJ; Eccles SA; Nutting CM
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):569-83. PubMed ID: 15270661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung cancer: looking ahead in 2004.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2004 Jan; 5(4):200. PubMed ID: 14967070
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the epidermal growth factor receptor in non-small cell lung cancer.
    Herbst RS; Bunn PA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5813-24. PubMed ID: 14676101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.
    Ettinger DS
    Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?
    Azim HA; Ganti AK
    Cancer Treat Rev; 2006 Dec; 32(8):630-6. PubMed ID: 17034953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor signaling in nonsmall cell lung cancer.
    Ganti AK
    Cancer Invest; 2010 Jun; 28(5):515-25. PubMed ID: 20073576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
    Ciardiello F; Tortora G
    Clin Cancer Res; 2001 Oct; 7(10):2958-70. PubMed ID: 11595683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors.
    Marshall J
    Cancer; 2006 Sep; 107(6):1207-18. PubMed ID: 16909423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
    Mendoza L
    Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.